INmune Bio Inc [INMB] stock is trading at $2.36, up 2.61%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The INMB shares have gain 12.92% over the last week, with a monthly amount drifted -69.03%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
INmune Bio Inc [NASDAQ: INMB] stock has seen the most recent analyst activity on July 01, 2025, when Scotiabank downgraded its rating to a Sector Underperform but kept the price target unchanged to $0.60 for it. Previously, BTIG Research downgraded its rating to Neutral on July 01, 2025. On January 28, 2025, Rodman & Renshaw initiated with a Buy rating and assigned a price target of $23 on the stock. Alliance Global Partners started tracking the stock assigning a Buy rating and suggested a price target of $20 on October 21, 2024. Raymond James initiated its recommendation with a Outperform and recommended $18 as its price target on September 27, 2024. Scotiabank started tracking with a Sector Outperform rating for this stock on August 22, 2024, and assigned it a price target of $22. In a note dated June 01, 2023, Robert W. Baird initiated an Outperform rating and provided a target price of $16 on this stock.
INmune Bio Inc [INMB] stock has fluctuated between $1.89 and $11.64 over the past year. Currently, Wall Street analysts expect the stock to reach $22 within the next 12 months. INmune Bio Inc [NASDAQ: INMB] shares were valued at $2.36 at the most recent close of the market. An investor can expect a potential return of 832.2% based on the average INMB price forecast.
Analyzing the INMB fundamentals
INmune Bio Inc [NASDAQ:INMB] reported sales of 0.05M for the trailing twelve months, which represents a growth of 257.14%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -830.46%, Pretax Profit Margin comes in at -815.92%, and Net Profit Margin reading is -815.92%. To continue investigating profitability, this company’s Return on Assets is posted at -1.08, Equity is -1.19 and Total Capital is -1.39. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.23 points at the first support level, and at 2.10 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.49, and for the 2nd resistance point, it is at 2.62.
Ratios To Look Out For
For context, INmune Bio Inc’s Current Ratio is 2.64. Also, the Quick Ratio is 2.64, while the Cash Ratio stands at 2.44. Considering the valuation of this stock, the price to sales ratio is 1254.80, the price to book ratio is 1.82.
Transactions by insiders
Recent insider trading involved Moss David J, Chief Financial Officer, that happened on Sep 30 ’24 when 10000.0 shares were purchased. President and CEO, Tesi Raymond Joseph completed a deal on Sep 12 ’24 to buy 15380.0 shares. Meanwhile, Chief Financial Officer Moss David J bought 7690.0 shares on Sep 12 ’24.
